Cypherpunk Technologies stock: $306 million Q3 profit on Zcash gain
Published on 11/17/2026 at 22:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMining Revenue and Treasury Growth
- Cypherpunk Technologies reported 9.913 million US dollars of mining revenue in its first operating quarter.
- The Zcash treasury reached 341,858.75 ZEC, equal to about 2.01% of circulating supply.
- Leap Therapeutics began a strategic process to secure funding or a transaction for sirexatamab.
Cypherpunk Technologies reported third-quarter 2026 results on November 16, 2026, with mining revenue emerging as the company began operating its Zcash fleet. The company recorded net income of 306.005 million US dollars for the quarter ended September 30, compared with a net loss of 3.303 million US dollars a year earlier, according to the Cypherpunk Technologies news release.
Mining Drives First Operating Profit
Mining revenue reached 9.913 million US dollars in the first quarter of operations, based on 8,967.29 ZEC mined from August 18 through September 30. The company reported an average fair value of 1,105.46 US dollars per ZEC and a mining cost of 104.33 US dollars per ZEC before depreciation.
Operating income was 2.606 million US dollars. Net income was driven primarily by a 330.846 million US dollar unrealized gain on an embedded derivative, reflecting the increase in ZEC from 400.09 US dollars on June 30 to 1,414.56 US dollars on September 30. The company also recorded 27.504 million US dollars in income-tax expense.
Zcash Holdings Expand
Cypherpunk said its treasury held 341,858.75 ZEC after October mining and open-market purchases, representing about 2.01% of circulating supply. Management continues to target holdings equal to at least 5% of the ZEC supply over time.
The company also reported a September letter of intent with Bitmain for next-generation Zcash mining machines, with a purchase commitment of up to 30.0 million US dollars and a refundable deposit of 6.0 million US dollars. Delivery is expected in mid-2027, subject to completion of the transaction.
Biotech Unit Seeks Strategic Path
Through its Leap Therapeutics subsidiary, Cypherpunk has started a strategic process for sirexatamab after Phase 2 DeFianCe study results, FDA Fast Track designation and alignment on a potential Phase 3 design. The process may involve independent financing or a strategic transaction, including a partnership, license, collaboration, sale or business combination.
Cypherpunk Technologies stock traded at 1.74 euros on Lang & Schwarz at 22:23 CET on Tuesday, November 17, 2026.
Cypherpunk Technologies at a glance
- Company: Cypherpunk Technologies Inc.
- ISIN: US52187K2006
- Ticker: CYPH
- Listing: Nasdaq
- Lang & Schwarz quote: 1.74 euros on November 17, 2026 at 22:23 CET
The Nasdaq Composite sets the broader market backdrop for the Nasdaq-listed company.
